These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12100090)
1. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Vachharajani NN; Shyu WC; Nichola PS; Boulton DW Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090 [TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235 [TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076 [TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776 [TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391 [TBL] [Abstract][Full Text] [Related]
7. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients]. Géraud G; Valette C Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800 [TBL] [Abstract][Full Text] [Related]
8. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers. Berges A; Walls C; Lener SE; McDonald SA Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of intranasal sumatriptan. Fuseau E; Petricoul O; Moore KH; Barrow A; Ibbotson T Clin Pharmacokinet; 2002; 41(11):801-11. PubMed ID: 12190330 [TBL] [Abstract][Full Text] [Related]
11. Onzetra Xsail--sumatriptan nasal powder. Med Lett Drugs Ther; 2016 Jul; 58(1499):92-3. PubMed ID: 27403783 [No Abstract] [Full Text] [Related]
12. [Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)]. Scheen AJ Rev Med Liege; 1997 Sep; 52(9):610-2. PubMed ID: 9441347 [No Abstract] [Full Text] [Related]
13. Parental satisfaction with sumatriptan nasal spray in childhood migraine. Pakalnis A; Kring D; Paolicchi J J Child Neurol; 2003 Nov; 18(11):772-5. PubMed ID: 14696905 [TBL] [Abstract][Full Text] [Related]
14. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study. Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816 [TBL] [Abstract][Full Text] [Related]
15. Zelrix: a novel transdermal formulation of sumatriptan. Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. Davis GA; Rudy AC; Archer SM; Wermeling DP Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403 [TBL] [Abstract][Full Text] [Related]
18. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340 [TBL] [Abstract][Full Text] [Related]
19. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]